Onesource Specialty Pharma Intrinsic Value
Onesource Specialty Pharma intrinsic value. Onesource Specialty Pharma (ONESOURCE) median intrinsic value is ₹418.25 from 7 valuation models (range ₹413–₹3445), vs current price ₹1377.80 — -69.6% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit ONESOURCE share price screener.
ONESOURCE Valuation Methods Summary — DCF, Graham Number & P/E
Onesource Specialty Pharma intrinsic value across 7 models vs current price ₹1377.80 — upside/downside and value range per method. Compare with Onesource Specialty Pharma value estimation to assess whether the stock is under or overvalued.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹413.34 | ₹330.67 - ₹496.01 | -70.0% | EPS: ₹1.60, Sector P/E: 22x |
| Book Value Method | asset | ₹3444.50 | ₹3100.05 - ₹3788.95 | +150.0% | Book Value/Share: ₹4859.17, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹2755.60 | ₹2480.04 - ₹3031.16 | +100.0% | Revenue/Share: ₹1433.33, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹2755.60 | ₹2480.04 - ₹3031.16 | +100.0% | EBITDA: ₹376.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹413.34 | ₹372.01 - ₹454.67 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹413.34 | ₹372.01 - ₹454.67 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹418.25 | ₹376.43 - ₹460.08 | -69.6% | EPS: ₹1.60, BVPS: ₹4859.17 |
ONESOURCE Intrinsic Value vs Market Price — All Valuation Models
Onesource Specialty Pharma fair value range ₹413–₹3445 vs current market price ₹1377.80 across 7 valuation models. Read Onesource Specialty Pharma dividend policy for the complete payout history and dividend yield track record.
ONESOURCE Intrinsic Value Analysis — Undervalued or Overvalued?
Onesource Specialty Pharma median intrinsic value ₹418.25, current price ₹1377.80 — Trading Above Calculated Value by 69.6%, margin of safety -100.0%.
What is the intrinsic value of ONESOURCE?
Based on our comprehensive analysis using 7 different valuation methods, the estimated intrinsic value of Onesource Specialty Pharma (ONESOURCE) is ₹418.25 (median value). With the current market price of ₹1377.80, this represents a -69.6% variance from our estimated fair value.
The valuation range spans from ₹413.34 to ₹3444.50, indicating ₹413.34 - ₹3444.50.
Is ONESOURCE undervalued or overvalued?
Based on our multi-method analysis, Onesource Specialty Pharma (ONESOURCE) appears to be trading above calculated value by approximately 69.6%.
ONESOURCE Financial Health — Key Ratios vs Industry Benchmarks
Onesource Specialty Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 0.3% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 21.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.21x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
ONESOURCE Cash Flow Quality — Operating & Free Cash Flow
Onesource Specialty Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹9 Cr | ₹-239 Cr | Positive Operating Cash Flow | 6/10 |
| March 2025 | ₹-68 Cr | ₹-169 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-107 Cr | ₹-107 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-163 Cr | ₹-197 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-416 Cr | ₹-762 Cr | Negative Cash Flow | 3/10 |